BayRay started operations in May 2019 as a drug discovery technology and product-focused innovation center. BayRay aims to bridge the innovation gap between academia and industry in the Chinese biomedical industry by partnering with world class academic centers and companies to develop cutting edge drug discovery technologies around early stage drug development projects. We focus on novelty and originality of early stage discovery science out of academia with the goal to create valuable intellectual property and core technologies that will become game changers in their respective fields. At present, all our projects involve small molecule drug discovery, one of our core strengths. In a second stage we will also add projects and technology platforms involving biologic drugs.
BayRay has defined the following criteria for selection of novel projects: (1) Unmet medical (or technological) need, (2) early stage project with high innovation potential, (3) qualified project team and feasibility of proof of concept studies at BayRay, and (4) intellectual property creation and market potential.